🔖
Bu Makaleye Atıf Yap
KAHRAMAN, S., ZİYREK, M. (2017). P2Y12 inhibition after thrombotic thrombocytopenic purpura remission. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 5, 416–417. https://ajindex.com/articles/365816
Dergiler / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 5
P2Y12 inhibition after thrombotic thrombocytopenic purpura remission
- Sayfa
- 416–417
- DOI
- —
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗Kaynakça (4)
- Doğan A, Özdemir B, Bal H, Özdemir E, Kurtoğlu N. Ticagrelor-associated thrombotic thrombocytopenic purpura. Anatol J Cardiol 2017; 17: 73-4.
- Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
- Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38: 845-53.
- Patel TN, Kreindel M, Lincoff AM. Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report. J Invasive Cardiol 2006; 18: E2113. Zhang T, Shen L, Hu L, He B. Optimal duration of dualantiplatelet therapy following drug-eluting stent implantation: a meta-analysis. J Clin Pharmacol 2013; 53: 345-51.